No abstract

No abstract

No abstract

No abstract

No abstract

No abstract

Somatosensory conduction time between the dorsal column nuclei and the cerebral cortex may be measured following median nerve stimulation by recording evoked potentials from both scalp and neck. Central conduction times were significantly increased relative to normal (5.6 +/ 0.5 msec) in 11 of 24 comatose patients. Results within 10 and 35 days of onset of coma were correlated with the final clinical outcome. Conduction times were independent of serum phenobarbital (0 to 630 mumol per liter) and of central body temperature (35.0 to 38.5 degrees C). Serial studies in coma demonstrated (1) short-term increases during temporary metabolic disorders, and (2) sustained increases with gradual recovery over many months, particularly after head injury.

Background: The administration of chemotherapy is associated with risk for morbidity. Management of chemotherapyrelated morbidity in veterinary oncology has been primarily supportive.Hypothesis: The purpose of this study was to evaluate the effect of prophylactic antimicrobial use on chemotherapyassociated morbidity in dogs with lymphoma or osteosarcoma.Animals: Dogs presenting with histologically confirmed osteosarcoma or lymphoma were eligible. Methods: Patients were randomized to receive placebo or trimethoprim-sulfadiazine for 14 days after their first doxorubicin chemotherapy. Both owner and clinician were blinded with respect to treatment. Patient assessment included CBC, physical examination and performance, and toxicosis grading on days 7 and 14. Investigated outcomes were hospitalization, suspicion of infection, gastrointestinal toxicity, neutropenia, nonhematologic toxicity, and quality of life.Results: Seventy-three dogs were enrolled; 34 had osteosarcoma, and 39 had lymphoma. Dogs receiving trimethoprimsulfadiazine (n 5 36) had a significantly reduced hospitalization rate (P 5.03), nonhematologic toxicity (P 5 0.039), grade 2-4 nonhematologic toxicity (P , .0001), grade 2-4 gastrointestinal toxicity (P 5 .007). and altered performance (P 5 .015). By group, dogs with osteosarcoma (n 5 34) that received the antimicrobial experienced fewer occurrences of nonhematologic toxicity (P 5.02) and less severe nonhematologic toxicity (P 5 .038). Dogs with lymphoma (n 5 39) had significant reductions in the occurrence of hospitalization (P 5.035), severity of nonhematologic toxicity (P 5 .036), and alterations of performance (P 5 .015).Conclusions: The use of prophylactic trimethoprim-sulfadiazine has benefit in reducing morbidity in dogs with osteosarcoma or lymphoma during the first 14 days after treatment with doxorubicin.